Summary
Stryker Corporation reported a solid third quarter for 2022, demonstrating resilience amidst a challenging macroeconomic environment. Net sales increased by 7.7% year-over-year, reaching $4,479 million, driven by strong unit volume growth across both its MedSurg and Neurotechnology and Orthopaedics and Spine segments. Despite inflationary pressures and supply chain disruptions impacting gross margins, the company maintained healthy operating income and significantly grew net earnings by 86.3% to $816 million, translating to diluted EPS of $2.14. This earnings growth was notably aided by a favorable tax settlement. The company also executed a significant strategic acquisition, completing the purchase of Vocera Communications for $2.6 billion, aiming to bolster its digital care coordination capabilities. While investing in future growth through R&D and strategic acquisitions, Stryker managed its cash flow effectively, although net cash from operations saw a decrease compared to the prior year, largely due to increased inventory build to mitigate supply chain risks. The company reaffirmed its financial strength and liquidity, positioning itself for continued growth.
Financial Highlights
50 data points| Revenue | $4.48B |
| Cost of Revenue | $1.70B |
| Gross Profit | $2.78B |
| R&D Expenses | $364.00M |
| SG&A Expenses | $1.46B |
| Operating Expenses | $1.97B |
| Operating Income | $808.00M |
| Net Income | $816.00M |
| EPS (Basic) | $2.16 |
| EPS (Diluted) | $2.14 |
| Shares Outstanding (Basic) | 378.40M |
| Shares Outstanding (Diluted) | 381.80M |
Key Highlights
- 1Stryker reported a 7.7% increase in net sales to $4,479 million for the third quarter of 2022, driven by strong unit volume growth in both key segments.
- 2Net earnings surged by 86.3% to $816 million, with diluted EPS of $2.14, significantly boosted by favorable tax settlements.
- 3The company completed the strategic acquisition of Vocera Communications for $2.6 billion, enhancing its digital care coordination offerings within the MedSurg and Neurotechnology segment.
- 4Gross profit margin saw a slight contraction to 62.1% from 63.5% year-over-year, attributed to increased costs from electronic component purchases and general inflationary pressures.
- 5Research, Development, and Engineering expenses increased by 19.0% for the quarter, reflecting continued investment in innovation and integration of acquisitions.
- 6Net cash provided by operating activities decreased to $1,621 million for the nine months ended September 30, 2022, from $2,263 million in the prior year, primarily due to increased inventory build to manage supply chain issues.
- 7Despite economic headwinds, Stryker ended the quarter with a strong balance sheet, including $1,420 million in cash and cash equivalents.